Clinical ResearchCardiometabolic RiskGenetic Inhibition of CETP, Ischemic Vascular Disease and Mortality, and Possible Adverse Effects
Key Words
Abbreviations and Acronyms
Cited by (0)
This work was supported by a Specific Targeted Research Project grant from the European Union, Sixth Framework Programme Priority (FP-2005-LIFESCIHEALTH-6) contract no. 037631; the Danish Medical Research Council; the Research Fund at Rigshospitalet, Copenhagen University Hospital; Chief Physician Johan Boserup and Lise Boserup's Fund; Ingeborg and Leo Dannin's Grant; Henry Hansen's and Wife's Grant; William Nielsen's Fund; and a grant from the Odd Fellow Order. Dr. Nordestgaard has received lecture and/or consultancy honoraria from AstraZeneca, Merck & Co., Inc., Pfizer Inc., Karo Bio, Omthera Pharmaceuticals, Inc., Abbott, Sanofi-Aventis, and Regeneron. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.